Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Domainex

- PMLiVE

NRG Therapeutics appoints Claus Sundgreen as Chief Medical Officer

Sundgreen previously held senior medical leadership positions across biotechnology and pharmaceutical companies

- PMLiVE

Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan

The company has been given manufacturing and marketing authorisation for the therapy

- PMLiVE

Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms

The platform will passively collect data to understand treatment responses in everyday life

- PMLiVE

NRG Therapeutics appoints Paul Thompson as Chief Development Officer

Thompson previously held senior roles at Mission Therapeutics and GSK

- PMLiVE

Mission Therapeutics advances Parkinson’s disease candidate

The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

- PMLiVE

PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

The US-based company develops light-based therapies for neurodegenerative conditions

- PMLiVE

Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

- PMLiVE

GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

- PMLiVE

Researchers develop new approach to target cells affected by motor neurone disease

The technique could lead to safer and more effective gene therapies for the neurodegenerative disease

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

The neurodegenerative condition currently affects nearly ten million people worldwide

- PMLiVE

LifeArc and King’s College London partner to accelerate treatment for motor neurone disease

The rare neurodegenerative disease affects one in every 300 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links